Key result
Adequate VTE prophylaxis is administered in only ~7% of patients hospitalized with severe active UC.
Why the study?
What is the rate of pharmacological venous thromboembolism prophylaxis prescription and administration in hospitalized patients with severe active ulcerative colitis?
Cohort (n=336)
No
What is the rate of pharmacological venous thromboembolism prophylaxis prescription and administration in hospitalized patients with severe active ulcerative colitis?
There is a significant gap in guideline-directed care, with only 7% of hospitalized patients with severe active ulcerative colitis receiving adequate pharmacological VTE prophylaxis.
Answers are grounded in this paper and cite their sources.
Underscores major VTE prophylaxis gap in severe UC hospitalizations; supports targeted QI efforts but leaves open impact on outcomes.
BACKGROUND: Hospitalised patients with inflammatory bowel disease are 1.5- to 3.5-fold more likely to develop venous thromboembolism compared to controls. Clinical guidelines recommend pharmacological prophylaxis. AIM: To determine the rate of pharmacological venous thromboembolism prophylaxis prescription and administration in a cohort of hospitalised patients with severe active ulcerative colitis and to assess predictors of failure to order pharmacological prophylaxis at 24 h. METHODS: This is a retrospective review of hospitalised patients with severe active ulcerative colitis, identified by ICD-9-CM discharge code 556.x, admitted to a single tertiary care hospital from 1 January 2005 to 31 August 2012. Adequate thromboembolism prophylaxis was defined as an order for low-dose unfractionated heparin two to three times daily, low-molecular weight heparin 40 mg daily or fondaparinux 2.5 mg daily ordered and administered for >80% of the admission. Patient related factors associated with failure to order prophylaxis at 24 h were accessed as secondary outcomes. RESULTS: Three hundred and thirty-six patients were hospitalised with severe active ulcerative colitis. Hospitalists had prescribed appropriate pharmacological prophylaxis by 48 h in only 37% of cases. Of these, nurses administered all prescribed doses in 18% of cases. Only 7% of patients (22/304, 95% CI: 5-11%) received adequate pharmacological prophylaxis for >80% of their hospitalisation. Hematochezia (P = 0.002), elevated platelets (P = 0.008), male gender coupled with younger age (P = 0.005) and admission on a biologic (P = 0.03) were associated with failure to order prophylaxis. CONCLUSION: Hospitalised patients admitted with severe active ulcerative colitis are not receiving appropriate pharmacological venous thromboembolism prophylaxis.
No takes yet. Share an insight, caveat, or question.
Pleet et al. (2014) conducted a cohort in Severe active ulcerative colitis (n=336). Pharmacological venous thromboembolism prophylaxis (unfractionated heparin, low-molecular-weight heparin, or fondaparinux) was evaluated on Incidence of adequate VTE prophylaxis (appropriately dosed pharmacological VTE prophylaxis ordered and administered for >80% of the hospitalization) (95% CI 5-11%). Adequate pharmacological venous thromboembolism prophylaxis was ordered and administered for >80% of the hospitalization in only 7% of patients with severe active ulcerative colitis.
Synapse has enriched 10 related papers. Consider them for comparative context: